Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD)

BACKGROUND: Users of guideline-recommended renin–angiotensin–aldosterone system (RAAS) inhibitors may experience disruptions to their treatment, e.g. due to hyperkalaemia, hypotension or acute kidney injury. The risks associated with treatment disruption have not been comprehensively assessed; there...

Descripción completa

Detalles Bibliográficos
Autores principales: Humphrey, Toby J L, James, Glen, Wittbrodt, Eric T, Zarzuela, Donna, Hiemstra, Thomas F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598122/
https://www.ncbi.nlm.nih.gov/pubmed/34804520
http://dx.doi.org/10.1093/ckj/sfab029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598122/
https://www.ncbi.nlm.nih.gov/pubmed/34804520
http://dx.doi.org/10.1093/ckj/sfab029

Ejemplares similares